Emitech
- Company typePrivate
- Founded2002
- HeadquartersFall River, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Emitech does
Emitech, Inc. is a biotechnology company founded in 2002 and headquartered in Fall River, Massachusetts that develops nanotechnology-based biosensors and optoelectronic devices for chemical and biological detection. Its platform centers on proprietary nanoporous silicon (NPSi) photonic crystals, electrochemical sensor arrays, and bio-nanocomposites engineered to deliver particle-per-trillion-level sensitivity for narcotics, explosives, and disease biomarkers. The product portfolio includes the OpiTest family (electrochemical wearable and bench-top detectors), OpiDrop (rapid fentanyl sweat/saliva/urine test), OpiSweat (wrist-worn wearable), Fenta-strips and Fenta-Test Cassettes (colorimetric lateral flow assays with 0.5 ng/mL LoD), and pipeline products CLEBO (women's health diagnostics) and a COVID-19 electrochemical immunosensor; underlying detection claims include 1 ng/mL fentanyl detection in sweat and explosives detection down to 150 femtograms.
The company's business model rests on SBIR/STTR federal grant funding — most notably a $2.5 million three-year NIH/NIDA Phase II grant (2022) for the wearable opioid sensor program, plus cumulative awards across MDA, USAF, US Army, US Navy, NSF and DHS — together with development contracts from private healthcare and life-sciences clients. Distribution today is essentially direct: R&D contracts to federal agencies and private-sector validation partners, with planned future sales of devices and disposable cartridges via direct channels and a recently signed manufacturing partnership with Linxens for scaling. Customer segments are vertically structured around federal defense and health agencies, private healthcare/life-sciences companies, and eventually consumer health end-users.
Emitech currently operates with 1-10 employees, is privately held and founder-controlled (Co-founder/CEO Marina Katayeva and CSO Dr. Igor A. Levitsky), and is in a pre-commercial execution phase building manufacturing partnerships, regulatory pathways, and channel readiness to monetize the electrochemical sensor platform.
Emitech firmographics
Firmographics- Name
- Emitech
- Legal name
- Emitech, Inc.
- Website
- https://emitechinc.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Emitech industry classification
Industry- Product category
- Biosensors & Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
- akta.pro secondary industries
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Emitech is headquartered
LocationHeadquarters
- HQ city
- Fall River
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Emitech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Government SBIR/STTR Contracts: Emitech generates revenue primarily through Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants from federal agencies including NIH/NIDA, NSF, MDA, US Army, US Navy, Department of Homeland Security, and Department of State. The company has received 8 Phase I and 3 Phase II SBIR/STTR contracts.
- Private Sector Contracts: Revenue from private sector clients in the life sciences and material science markets, including development agreements and product validation contracts.
- Product Sales (Future): Once products reach market, revenue will be generated from sale of electrochemical devices (OpiTest, OpiDrop, OpiSweat), fentanyl test strips (Fenta-strips, Fenta-Test Cassette), and disposable cartridges for wearable devices.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Emitech product offering
Product offeringCore offering
Emitech develops and is commercializing nanotechnology-based electrochemical biosensors and lateral flow immunoassay devices for ultra-sensitive detection of narcotics (opioids/fentanyl), explosives, and disease biomarkers. Current and pipeline products include wearable and bench-top electrochemical detectors (OpiTest, OpiDrop, OpiSweat) and rapid colorimetric fentanyl test strips/cassettes, with women's-health (CLEBO) and COVID-19 electrochemical immunosensors under development. The company primarily delivers these technologies via government SBIR/STTR R&D contracts and is preparing direct sales and OEM manufacturing channels for commercialization.
Product overview
Emitech offers a portfolio of electrochemical and lateral flow immunoassay products for narcotics detection and medical diagnostics. Core products include OpiTest (electrochemical multi-matrix detection platform), OpiDrop (fentanyl-specific e-sensor), OpiSweat (wearable wrist device), Fenta-strips, and Fenta-Test Cassettes (colorimetric rapid tests). These products share foundational electrochemical sensor technology and Bluetooth connectivity for wireless data transfer. Future pipeline includes CLEBO (women's health diagnostics) and COVID-19 rapid testing platform. All products are under development with SBIR funding from NIH/NIDA.
Differentiator
Problem solved
Functional benefit
Brands
- OpiTest: Electrochemical devices for rapid and accurate narcotic detection in sweat (wearable), saliva, urine, and dissolved medication. Narcotic panel includes fentanyl with a limit of detection (LoD) of 1ng/ml.
- OpiDrop
- OpiSweat
- Fenta-strips
- Fenta-Test Cassette
- CLEBO
Products and services
- OpiTest Electrochemical detection platform for rapid and accurate narcotic detection in sweat (wearable), saliva, urine, and dissolved medication, with a fentanyl limit of detection of 1 ng/ml. Targeted at government agencies, healthcare providers, and law-enforcement/laboratory users requiring multi-matrix rapid opioid screening.
- OpiDrop Urine/saliva/pill electrochemical sensor (e-sensor) for rapid fentanyl detection with LoD of 1 ng/ml, 10-minute time-to-result, and wireless data transmission to phone/tablet/PC. Targeted at point-of-care testers, harm-reduction programs, and clinical/research users needing fast fentanyl-specific screening.
- OpiSweat Wrist-worn wearable device for non-invasive, rapid narcotics detection in human sweat with quantitative results in 10 minutes and wireless connectivity to smartphone/tablet/PC. Features a reusable device with disposable cartridges for cost-effective continuous monitoring, targeted at medical monitoring, addiction treatment, and at-risk-workforce applications.
- Fenta-strips Colorimetric lateral flow immunoassay strip sensors for rapid fentanyl detection with LoD of 0.5 ng/ml, providing semi-quantitative concentration readings well below the 20 ng/ml typical of market-available strips. Targeted at harm-reduction organizations, clinicians, and field-deployment users needing low-cost rapid fentanyl screening.
- Fenta-Test Cassette Colorimetric cassette-format lateral flow immunoassay for rapid fentanyl detection, providing semi-quantitative results indicating fentanyl concentration ranges through color-change readouts. Targeted at users needing an easy-to-read cassette format for fentanyl field-testing.
- CLEBO Under-development portable non-invasive rapid diagnostic device using menstrual fluid and blood to target gynecological cancers, breast cancer, sexually transmitted infections, Alzheimer's disease, and physiological parameters (pH, glucose, cholesterol, ketones, salts) with Bluetooth connectivity. Targeted at consumers and clinicians seeking home-based women's-health and disease-monitoring diagnostics.
- COVID-19 Rapid Test Under-development non-invasive rapid electrochemical immunosensor for COVID-19 providing 5–10 minute results at $3–5 per test cartridge, with a limit of detection of 1,000–10,000 virion/ml (comparable to PCR) and wireless communication to smartphone/PC. Targeted at point-of-care users, employers, and healthcare providers needing PCR-grade rapid screening.
Quantifiable outcome
- Limit of detection of 1 ng/ml for opioids in human sweat (vs. 10-20 ng/ml market standard)
- +5 more outcomes
Companies that use Emitech
Customer profileSegments3 records
Ideal customer profiles2 records
Emitech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Emitech partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- LinxenscoreEmitech teams up with Linxens, a global leader in electronics production with Healthcare solutions in Biosensor, Stick to skin and Track&Trace, for a successful manufacturing partnership. Linxens leads healthcare business development specializing in biosensors and wearable solutions with 15+ years experience in healthcare, digital security, and telecommunications.
- Inertia, Inc.coreEmitech forged a connection with Inertia, Inc. leveraging their expertise in low-volume production and commercialization of innovative biomedical devices.
- M2D2 (Massachusetts Medical Device Development Center)minorEmitech was chosen among top startups for the competitive M2D2 accelerator program. This strategic move connects Emitech to vital expertise and resources, propelling technology development.
- CytoDiagnostics, Inc.coreStrategic alliance with CytoDiagnostics, Inc., a partner and manufacturer of components for OpiTest, an electrochemical detection device. CytoDiagnostics developed unique approaches to ensure highest quality antibody conjugates with ultra-low LOD for fentanyl detection.
- MassBio (Massachusetts Biotechnology Council)minorEmitech joined MassBio, a community of leaders dedicated to growing the life sciences industry and adding value to the healthcare system. MassBio provides networking, advocacy, and resources for biotechnology companies in Massachusetts.
- Mansfield Bio-IncubatorminorEmitech became a member of Mansfield Bio-Incubator, Biotech Entrepreneurship in the Boston area. The incubator provides mentorship, resources, and networking opportunities for biotech startups, culminating in pitch competition participation and nondilutive funding awards.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Emitech competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Emitech social profiles
Digital presenceEmitech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emitech leadership team
Management profileNumber of profiles
Profiles7 records
Emitech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emitech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emitech
What does Emitech do?
Emitech develops and is commercializing nanotechnology-based electrochemical biosensors and lateral flow immunoassay devices for ultra-sensitive detection of narcotics (opioids/fentanyl), explosives, and disease biomarkers. Current and pipeline products include wearable and bench-top electrochemical detectors (OpiTest, OpiDrop, OpiSweat) and rapid colorimetric fentanyl test strips/cassettes, with women's-health (CLEBO) and COVID-19 electrochemical immunosensors under development. The company primarily delivers these technologies via government SBIR/STTR R&D contracts and is preparing direct sales and OEM manufacturing channels for commercialization.
Is Emitech a public or private company?
Emitech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Emitech founded?
Emitech was founded in 2002. It employs 1 to 10 people.
Where is Emitech based?
Emitech is headquartered in Fall River, United States, in the North America region.
How does Emitech make money?
Three revenue lines are on record. Government SBIR/STTR Contracts are the primary driver. The others are private Sector Contracts and product Sales (Future).
Does Emitech have an API?
No public API is recorded for Emitech.
What industry is Emitech in?
Emitech's product category is Biosensors & Diagnostic Devices. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 334510 and its SIC code is 3845.